Judith Miles (92 years old), one of the first people to be vaccinated against COVID-19 in Tasmania, Australia’s island state – Photo: ABC NEWS
On September 10, the US Centers for Disease Control and Prevention (CDC) published three studies showing the specific level of effectiveness of the COVID-19 vaccine in preventing infection, hospitalization and death from COVID-19. COVID-19.
Reduce risk died 11 times
Of the three studies by the US CDC, there was one study with more than 600,000 cases of COVID-19 in 13 states, about a quarter of the US population, between April and July of this year. Results showed that unvaccinated people were 4.5 times more likely to contract COVID-19, 10 times more likely to be hospitalized, and 11 times more likely to die than those who had received the full dose.
“Vaccines still work. The bottom line is that we have the scientific tools needed to overcome this pandemic,” – Dr. Rochelle Walensky, director of the US CDC, said at a press conference of the US CDC. The White House on September 10.
The vaccine is still considered effective in preventing COVID-19 hospitalizations and deaths even with Delta being the dominant variant in the US, but its effectiveness in prevention has also decreased from 91% to 78%.
The other two studies also showed that the vaccine’s effectiveness in preventing hospitalization was reduced with older age. For example, in one study, this effect was 95% in people aged 18-64 years old, but in people 65 and older it was only 80%. The results of these studies may help determine which populations need additional doses.
There are still many unvaccinated cases in the US, including millions of children under 12 who have not been vaccinated. “What I want to reiterate is that still more than 90% of people hospitalized with COVID-19 today are unvaccinated cases,” warned Ms. Rochelle Walensky.
Works even for Delta
To date, there have been many studies demonstrating that COVID-19 vaccines licensed for use around the world are effective in preventing a significant number of severe cases, hospitalizations and deaths from COVID-19.
New research by the US CDC shows that the effectiveness of the Moderna vaccine in preventing COVID-19 hospitalization is 95%, that of Pfizer-BioNTech is 80% and that of Johnson & Johnson is 60%. These are the three approved COVID-19 vaccines in the US.
“The COVID-19 vaccine is still very effective in preventing what we fear most: severe illness, hospitalization and death,” said Dr. Richard Besser, president of the Robert Wood Johnson Foundation (USA).
Meanwhile, on September 10, The Jerusalem Post reported that Bahrain, in cooperation with Columbia University (USA) had just conducted research on four COVID-19 vaccines, including vaccines from Pfizer-BioNTech, Sputnik V , AstraZeneca and Sinopharm.
The study is based on data from 1,003,960 vaccinated people in Bahrain between December 2020 and July 2021 and 245,876 unvaccinated people.
Accordingly, about 82.2% of the 10,447 people hospitalized with COVID-19 in the Gulf country are unvaccinated. The remaining 16.1% of hospitalized patients received Sinopharm vaccine, 0.7% injected Sputnik V, 0.43% injected AstraZeneca and 0.38% injected Pfizer- BioNTech.
Of the 1,451 people hospitalized in the intensive care unit (ICU), 1,309 people (accounting for 90.2%) have not been vaccinated, 138 have been vaccinated with Sinopharm, 3 have received AstraZeneca and 1 have injected Pfizer-BioNTech. There were no cases of injection of Sputnik V requiring admission to the ICU.
Of the 976 people who died from COVID-19, 857 people (accounting for 87.8%) were not vaccinated, 112 deaths were injected with Sinopharm, 3 people were injected with Sputnik V, 3 people were injected with Pfizer, and 1 person was vaccinated. AstraZeneca.
“We believed early on that a COVID-19 vaccine would help limit the spread of the virus, but the main goal of vaccination is to reduce complications in the case of infection and reduce hospitalizations and deaths.” – said Dr Manaf AlQahtani, one of the study’s authors and a member of Bahrain’s national health team dealing with COVID-19.
The expert added: “This study helps shape future policies on vaccination globally, and Bahrain has made a huge mark in the scientific community by providing this kind of data.” .